NextCure (NASDAQ:NXTC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 422.88% from the company’s previous close. Separately, Needham & […]
Related Keywords
, Nextcure Inc , Needham Company , Acuitas Investments , Marquette Asset Management , Cable Car Capital , Get Free Report , Asset Management , Nextcure Daily , Nextcure , Nasdaq Nxtc , Nxtc , Medical , Reiterated Rating , Hc Wainwright ,
vimarsana.com © 2020. All Rights Reserved.